Objectives: To report our clinical experience with a percutaneous fetoscopic 3-layer technique for the treatment of large open spina bifida defects.
Methods:
Antenatal treatment of open spina bifida was performed between 16-27 6/7 weeks under general anesthesia using a percutaneous fetoscopic approach with partial CO2 insufflation of the uterine cavity, as previously described. If primary skin approximation was not possible over a biocellulose patch, a 3-layer closure using a bilaminar skin substitute composed of 2 layers -one silicone and one dermal matrix-was placed over the biocellulose patch. The skin was then approximated using a continuous running suture. Patients were delivered by Caesarean section. The surgical site was assessed at birth. Long term neurological follow up was performed as previously described. Results: A 3-layer closure was needed in 13/47 (27.7%) cases. In 12/13 cases, the large lesion was a myeloschisis. In all cases, the hindbrain herniation resolved. Eleven of the 13 cases have already delivered, and the skin substitute was found in all cases. In 3/11 cases, postnatal additional repair was needed and in the remaining 8 cases the silicone layer of the bilaminar skin substitute detached spontaneously from the dermal matrix (average 25,3 days after birth). A new epidermis subsequently covered the dermal matrix with complete closure by secondary intention. OR time was significantly longer in cases requiring the 3-layer closure. The mean follow-up was 9.8 months, with similar outcomes as previously reported.
Conclusions:
Large open spina bifida defects may be successfully treated in utero using a 3-layer closure involving a bilaminar skin substitute over a biocellulose patch. In all cases antenatal correction the hindbrain occurred. Long term follow up continues to reveal encouraging results. Further experience is needed to assess the risks and benefits of our surgical technique for the antenatal management of large open spina bifida defects. Objectives: Intra-amniotic insufflation with CO 2 gas has been used to improve visualisation and access for minimally invasive fetal surgery with increased complications for preterm premature rupture of membrane and preterm birth. We tested the hypothesis that CO 2 gas exposure to the amniotic fluid (AF) decreases pH and causes fetal membrane damage. Methods: In-vitro study was performed to expose fetal membrane explants (n=4; 32-34 weeks, elective Caesarean section for vasa previa and accreta) and AF in 100% CO 2 in air-tight hypoxia cell culture chamber over 120 minutes. Then, the explants were cultured in AF exposed to CO 2 for 24 more hours at normal CO 2 conditions. For controls, the explants were cultured in corresponding AF over the same period. Similar experiments were conducted in CM. AF and CM were analysed for pH. Explants were analysed for cell death (TUNEL staining) and collagen architecture (Picrosirius red staining visualised under polarised microscopy). Results: AF pH decreased from 7.5 to 6.5 with exposure to CO 2 . The apoptosis in amniotic epithelium was increased after CO 2 exposure (p<0.01) compared in non-exposed explants ( Figure 1 ). The collagen architecture appeared changed from long compact fibres to thin fragmented CO 2 exposed explants vs. normal appearing in the non-exposed explants. There was increased edema of the amniotic membrane in the CO 2 exposed explants. Conclusions: CO 2 exposure of decreases pH of AF and causes fetal membrane damage through cell death and disruption of collagen matrix in the amniotic membranes, and further studies are needed to explore alternative options.
Supporting information can be found in the online version of this abstract Objectives: Open fetal surgery became standard of care for myelomeningocele (MMC) after the MOMS trial and have encouraged many centres to enable them to be performed this procedure and broadening their indications. We reviewed the outcomes from our centre for MMC repair and others fetal conditions including data from surgery and perinatal period. Methods: A total of 211 open fetal surgeries were performed including 203 myelomeningoceles according MOMS criteria; Encephalocele (4); Congenital high airway obstruction syndrome (2); Congenital cystic adenomatoid malformation (1) and cervical myelomeningocele (1) using an alternative surgical approach developed in our institution during the last five years. The surgeries were undertaken with the same team with expertise in open fetal surgical and prepared to handle maternal and fetal complications. Results: All procedures were performed as scheduled and there was no maternal death. Myelomeningocele: GA at surgery 25 weeks (24-26); Surgery time 117 minutes (106-148); Interval between surgery and birth 52.9 days (5-89); Preterm labour 17.1%; PROM 20.6%; Placental abruption 1.0%; Dehiscence of uterine suture 3.5%; GA at delivery 34 weeks (26-37); GA <30 weeks 6.0%; Weight 2,210g (680-3,515); Perinatal death 1,9%; Reversal of hindbrain herniation at birth 72.9% and ventriculoperitoneal shunt insertion 2.5%. Other fetal anomalies: GA at surgery 25 weeks (24-27); Surgery time 141 minutes (113-168); Interval between surgery and birth 48.6 days (7-71); Preterm labour 25%; PROM 37.5%; GA at delivery 33 weeks (25-36); GA <30 weeks 12.5%; Weight 2,138g (1,115-3,035). There was no placental abruption, dehiscence of uterine suture and perinatal death. Conclusions: This experience using a novel surgical technique for open fetal surgery showed similar results of MOMS trial for myelomeningocele repair without the stapler device and, also proved to be safe and effective for other indications not included in the MOMS criteria and for others fetal anomalies. Objectives: Incidental finding of asymptomatic endometrial polyps is common. 44.4% of polyps in premenopausal women and 36.1% in postmenopausal women are asymptomatic. Pre-malignant or malignant changes are only found in 1.7% premenopausal and 5.4% postmenopausal women. These changes are less common in asymptomatic women in whom expectant management could be a safe management option. The main objective of this study was to assess the change in polyp's size and the development of abnormal bleeding in women who were managed expectantly. Methods: We retrospectively searched our ultrasound clinic database between July 1997 and September 2015 to identify women aged ≥18 years with endometrial polyp that were managed expectantly for ≥6 months. All women were examined at least twice by a single expert ultrasound operator with a minimum interval of 6 months between the examinations. We excluded women who were using hormonal contraception, HRT or medication that affected the endometrium such as tamoxifen. Results: 3008 women were diagnosed with endometrial polyps between July 1997 and September 2015. Among them, 112 women met inclusion criteria. Mean age of women at initial scan was 54.1 years (range, 25-93) . 67/112 (60%) women were postmenopausal. Median examination interval between initial and final scans was 22.5 months (range, 6-136); majority of women (104/112, 93%) had a single polyp. 75/112 (67%) women were initially asymptomatic of abnormal uterine bleeding. 11/75 (15%) women later developed abnormal bleeding during follow-up period. Patients' age, presence of a pedicle vessel on Doppler examination, polyps' size or growth rate were not predictive of women who would become symptomatic. 7/112 (6.3% (95% CI 1.8-10.7)) had spontaneous complete regression of polyp. Conclusions: Our study did not find that it was useful to routinely monitor asymptomatic endometrial polyps which appeared benign on ultrasound, as the change in polyp's size was not predictive of future development of abnormal bleeding; a small proportion of polyps also undergo spontaneous regression.
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